Lymphoma Research

Current Clinical Trial Research Trials

ACCEPT

Info: ACCEPT Trial Registration
Type: Diffuse large B cell lymphoma
Centres: Oxford
Description: Phase I/II R-CHOP+acalabrutinib, front-line DLBCL

ANIMATE

Info: ANIMATE Trial Registration
Type: Hodgkin Lymphoma
Centres: Oxford
Description: Single-arm, phase II, multi-centre study of the safety and efficacy of nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory classical Hodgkin lymphoma patients

APOLLO

Info: Pending - study will open Q1 2020
Type: Diffuse Large B Cell Lymphoma
Centres: Oxford
Description: Phase II non-randomised trial in front line setting in which patients receive polatuzumab vedotin with either R-GCP or R-mini-CHP depending on cardiac co-morbidities.

ASTX660

Info: ASTX660 Registration
Type: Peripheral and Cutaneous T-cell lymphoma
Centres: Oxford
Description: Single arm phase I/II assessing the IAP inhibitor ASTX660 in advanced solid tumours and lymphoma (peripheral and cutaneous T-cell lymphoma only cohorts open)

AVAIL-T

Info: AVAIL-T Trial Registration
Type: Relapsed/Refractory Peripheral T-cll Lymphoma (PTCL)
Centres: Oxford
Description: Avelumab in relapsed / refractory PTCL

AVENUE

Info: AVENUE Registration
Type: Advanced Classical Hodgkin lymphoma
Centres: Oxford
Description: Single arm phase II assessing avelumab (PDL1 inhibitor) prior to chemotherapy as 1st line treatment in advanced classical Hodgkin Lymphoma.

BI-1206

Info: BI-1206 Trial Registration
Type: B-cell NHL, CLL and WM
Centres: Oxford
Description: Phase I/II using an anti-CD32b antibody +/- rituximab in R/R NHL and CLL

Cardiac Care

Info: Cardoac Care Registration
Type: Non Hodgkin lymphoma
Centres: Oxford, Milton Keynes
Description: Randomised study for patients with non-Hodgkin lymphoma or breast cancer due to receive full dose anthracycline based chemotherapy. Trial will assess the impact of combined beta-blocker and ACE inhibitor therapy on cardiac MRI markers of

ENRICH

Info: ENRICH Trial Registration
Type: Mantle Cell lymphoma
Centres: Oxford, Milton Keynes
Description: Ibrutinib and rituximab in front line elderly mantle cell lymphoma

Maple

Info: Maple Trial Registration
Type: Diffuse large B cell lymphoma
Centres: Oxford, Bucks, Milton Keynes
Description: Tissue and data collection project in front line DLBCL

PETRea

Info: PETRea Registration
Type: Follicular Lymphoma
Centres: Oxford
Description: Randomised study in frontline treatment to determine the efficacy of maintenance rituximab in patients achieving CMR on end of induction PET scan. 

PRISM (ACE-LY-111)

Info: PRISM (ACE-LY-111) Registration
Type: Relapsed / refractory aggressive NHL
Centres: Oxford
Description: Platform study assessing various acalabrutinib-based combinations in relapsed / refractory DLBCL and other aggressive NHLs.

RIVA

Info: RIVA Trial Registration
Type: Relapsed/refractory B-cell non-Hodgkin Lymphoma
Centres: Oxford
Description: Phase II rituximab + varilumab in R/R NHL

RomiCar

Info: RomiCar Trial Registration
Type: Peripheral T Cell lymphoma
Centres: Oxford
Description: Phase I/II romidepsin and carfilzomib in R/R PTCL

TIDAL

Info: TIDAL Trial Registration
Type: Post transplant Lymphoproliferative disorder (PTLD)
Centres: Oxford
Description: Ibrutinib + Rituximab as first line treatment for PTLD

Unity-NHL

Info: Unity-NHL Trial Registration
Type: Diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma, SLL
Centres: Oxford
Description: Phase II umbrelisib + ublituximab +/- bendamustine in R/R NHL – DLBCL, FL, MZL, SLL

5F9003 trial

Info: 5F9003 trial Trial Registration
Type: Non-Hodgkin lymphoma
Centres: Oxford, Milton Keynes
Description: Phase I/II using an anti-CD47 antibody in combination with rituximab in R/R DLBCL and follicular lymphoma.